TechBio Cytomos has launched a new benchtop cell analyser called Celledonia, which uses the company’s AuraCyt platform.

Celledonia has been designed to provide cell-specific insights for modalities including monoclonal antibodies (mAbs), T cell immunotherapies, and induced pluripotent stem cells (iPSCs).

The new technology could help to:

• Predict cell health, type, and functions for T cell-based immunotherapy development
• Provide near-real time information about the state and age of cell populations
• Signal optimal time for harvesting
• Select high-producing, stable clones for CHO CLD of mAbs
• Inform pluripotent expansion and differentiation strategy for stem cells.

The AuraCyt platform integrates a proprietary semiconductor chip with narrow-channel fluidics that focus cells (5-30μm) close to the surface of the chip. As the cells pass through an electric field, the sensors provide a unique ‘fingerprint’ of the cell, analysing a range of cell features simultaneously.

Cytomos CEO David Rigterink commented: “By harnessing the power of dielectric spectroscopy and microelectronics, we can improve the pace and accuracy of single cell analysis. The technology fits into an evolving landscape of next-generation therapies that are driving the need for radical advances in cell analytics.”

Diana Spencer, Senior Digital Content Editor, DDW